Cover Image

Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty

Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with a high affinity for dopamine D2 and D1 receptors and the serotonin transporter. It is unusual in that it controls serotonin, dopamine, and glutamate neurotransmission concurrently, all of which have been implicated in severe mental illne...

Full description

Saved in:
Bibliographic Details
Main Author: Mohamed, Wael Mohamed Yousef
Format: Book Chapter
Language:English
Published: Elsevier 2025
Subjects:
R Medicine (General)
Online Access:http://irep.iium.edu.my/116442/7/116442_Atypical%20antipsychotic%20lumateperone%20beyond%20schizophrenia.pdf
http://irep.iium.edu.my/116442/
https://www.sciencedirect.com/science/article/abs/pii/B9780443157028000282
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.iium.irep.116442
record_format dspace
spelling my.iium.irep.1164422024-12-05T07:51:18Z http://irep.iium.edu.my/116442/ Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty Mohamed, Wael Mohamed Yousef R Medicine (General) Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with a high affinity for dopamine D2 and D1 receptors and the serotonin transporter. It is unusual in that it controls serotonin, dopamine, and glutamate neurotransmission concurrently, all of which have been implicated in severe mental illness. Consider it a multitargeted ligand and multifunctional modulator of the serotoninergic system with possible precognitive, antipsychotic, antidepressant, and anxiolytic properties. While lumateperone has been explored as a new agent for schizophrenia therapy, it also provides a unique therapeutic option for a range of other psychiatric and neurological diseases, including behavioral signs of dementia or Alzheimer's disease, sleep problems, and bipolar depression. Additionally, it had a better safety profile than placebo, with no significant extrapyramidal side effects, hyperprolactinemia, or changes in cardiometabolic or endocrine characteristics. Additional study is needed to validate and analyze lumateperone's effectiveness, as well as to identify prospective therapeutic targets. This article gives a comprehensive overview of the most notable results and potential future applications of this chemical in personalized medicine, particularly for neurodegenerative diseases. Elsevier 2025 Book Chapter PeerReviewed application/pdf en http://irep.iium.edu.my/116442/7/116442_Atypical%20antipsychotic%20lumateperone%20beyond%20schizophrenia.pdf Mohamed, Wael Mohamed Yousef (2025) Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty. In: Essential Guide to Neurodegenerative Disorders Mechanistic, Diagnostic and Therapeutic Advances. Elsevier, London, UK, pp. 461-467. ISBN 9780443157028 https://www.sciencedirect.com/science/article/abs/pii/B9780443157028000282 10.1016/B978-0-443-15702-8.00028-2
institution Universiti Islam Antarabangsa Malaysia
building IIUM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider International Islamic University Malaysia
content_source IIUM Repository (IREP)
url_provider http://irep.iium.edu.my/
language English
topic R Medicine (General)
spellingShingle R Medicine (General)
Mohamed, Wael Mohamed Yousef
Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
description Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with a high affinity for dopamine D2 and D1 receptors and the serotonin transporter. It is unusual in that it controls serotonin, dopamine, and glutamate neurotransmission concurrently, all of which have been implicated in severe mental illness. Consider it a multitargeted ligand and multifunctional modulator of the serotoninergic system with possible precognitive, antipsychotic, antidepressant, and anxiolytic properties. While lumateperone has been explored as a new agent for schizophrenia therapy, it also provides a unique therapeutic option for a range of other psychiatric and neurological diseases, including behavioral signs of dementia or Alzheimer's disease, sleep problems, and bipolar depression. Additionally, it had a better safety profile than placebo, with no significant extrapyramidal side effects, hyperprolactinemia, or changes in cardiometabolic or endocrine characteristics. Additional study is needed to validate and analyze lumateperone's effectiveness, as well as to identify prospective therapeutic targets. This article gives a comprehensive overview of the most notable results and potential future applications of this chemical in personalized medicine, particularly for neurodegenerative diseases.
format Book Chapter
author Mohamed, Wael Mohamed Yousef
author_facet Mohamed, Wael Mohamed Yousef
author_sort Mohamed, Wael Mohamed Yousef
title Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
title_short Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
title_full Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
title_fullStr Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
title_full_unstemmed Atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
title_sort atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
publisher Elsevier
publishDate 2025
url http://irep.iium.edu.my/116442/7/116442_Atypical%20antipsychotic%20lumateperone%20beyond%20schizophrenia.pdf
http://irep.iium.edu.my/116442/
https://www.sciencedirect.com/science/article/abs/pii/B9780443157028000282
_version_ 1817841096465580032
score 13.223943

Similar Items